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Abstract
To understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who
experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3
+ T cells,
neutrophils, CD11c
+ and CD83
+ myeloid dendritic cells (DCs), but no increase in CD1c
+ resident myeloid DCs. In relapsed
lesions, there were many CD11c
+CD1c
2, inflammatory myeloid DCs identified by TNFSF10/TRAIL, TNF, and iNOS. CD11c
+
cells in relapsed lesions co-expressed CD14 and CD16 in situ. Efalizumab induced an improvement in many psoriasis genes,
and during relapse, the majority of these genes reversed back to a lesional state. Gene Set Enrichment Analysis (GSEA) of the
transcriptome of relapsed tissue showed that many of the gene sets known to be present in psoriasis were also highly
enriched in relapse. Hence, on ceasing efalizumab, T cells and myeloid cells rapidly enter the skin to cause classic psoriasis.
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Introduction
Efalizumab (anti-CD11a, Raptiva, Genentech) is a fully
humanized monoclonal antibody to CD11a, the a-chain of
lymphocyte function-associated antigen (LFA-1), which is present
on many leukocytes. Although LFA-1 interacts with intracellular
adhesion molecules (ICAMS) for leukocyte migration into tissues,
antigen-presentation to T cells, and interaction with keratinocytes,
the most important therapeutic mechanism of action of efalizumab
appears to be via blockade of lymphocyte trafficking [1]. In
addition, patients on efalizumab may experience an unusual form
of T cell hyporesponsiveness [2], and fail to make effective
antibodies to a neoantigen [3].
An investigator-initiated study was conducted to further evaluate
the mechanism of action of efalizumab, in 30 patients with
moderate-to-severe psoriasis. Patients were given 12 weeks
treatment with 1 mg/kg/week subcutaneous efalizumab, followed
by a 12-week period of observation. However, 8 of the first 20
patients suffered from a rapid return of their psoriasis in the post-
treatmentperiod.The designofthe studywassubsequentlychanged
to treat the remaining 10 patients with efalizumab for the full 24
weeks of the study. Patients were then transitioned to an alternative
treatment at the end of the study, predominantly cyclosporine [4].
The National Psoriasis Foundation Medical Advisory Board has
proposed standard definitions of worsening of disease when
psoriasis treatment is discontinued, including relapse and rebound
[5,6]. Relapse is defined as loss of 50% of Psoriasis Activity and
Severity Index (PASI) improvement from baseline in patients who
achieve a clinically meaningful response. Relapse in the 12 weeks
of follow up after discontinuation of efalizumab therapy was
observed in 86% of patients who had achieved a PASI-75. The
relapse was often gradual, but some patients experienced a rapid
return of disease. Rebound is said to occur if the PASI is 125% or
greater than baseline, or if new generalized pustular, erythroder-
mic or more inflammatory psoriasis occurrs within 3 months of
stopping therapy. In a pooled analysis of 1316 patients in clinical
studies with efalizumab, 188 (14%) experienced a rebound during
the 12 week follow-up period [5,6].
When this study began in 2002, efalizumab was not FDA
approved for psoriasis. However, it was subsequently approved in
2003 for the treatment of moderate-to-severe psoriasis vulgaris.
Efalizumab was voluntarily withdrawn by Genentech in April
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leukoencephalopathy, a rare and usually fatal infection caused by
the reactivation of polyomavirus JC in the central nervous system
of immunocompromised individuals [7,8]. Thus, although this is
not an agent in use at the present time, precious clinical material
was available to study LFA-1 integrin blockade at a cellular and
molecular level.
Eight patients experienced a clinical relapse out of the first 20
patients. Our study demonstrated a marked increase in CD11c
+
inflammatory dendritic cells (DCs) and T cells, but not macro-
phages or resident DCs, at the time of disease relapse compared to
the end of the treatment period. The present study gives us insights
into the mechanism of action of efalizumab, which may be used in
the future as an orphan drug, as well as the potential effects of
integrin blockade with other agents. Furthermore, this study helps
to elucidate the mechanism of new lesion development in psoriasis.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement
Thirty-one adult patients with moderate-to-severe psoriasis
vulgaris were enrolled in this Rockefeller University Institu-
tional Review Board-approved study (Figure 1), clinicaltrials.gov
NCT00115076 between August 2003 and June 2007. All patients
gave written informed consent. Research was conducted in accor-
dance with the Declaration of Helsinki principles.
Study design
Patients were treated with weekly subcutaneous injections of
1 mg/kg of efalizumab for 12 weeks, and then the first 20 patients
were observed weekly for an additional 12 weeks, and the last 10
patients were treated for 24 weeks. Skin biopsies were obtained at
baseline from an uninvolved area (non-lesional, NL) and an index
psoriatic plaque lesion (LS). Biopsies were also taken from lesions
at weeks 2, 6, and 12 of efalizumab treatment. An additional
punch biopsy was obtained from patients whose disease worsened
after treatment was finished (n=8).
Immunohistochemistry
Immunohistochemistry was performed for leukocytes in patients
who experienced a relapse (n=8). Frozen tissue sections were
stained with haematoxylin (Thermo Fisher Scientific) and eosin
(Shandon) or with murine anti-human monoclonal antibodies as
listed in Table S1. Biotin-labelled horse anti-mouse antibodies
(Vector Laboratories) were used to amplify the primary signal with
an avidin-biotin complex and developed with chromogen-3-
amino-9-ethylcarbazole (Sigma Aldrich). Positively stained cells
per millimeter were manually counted using image analysis
software (Image J, version 1.386, National Institutes of Health),
and reported per mm linear length of the epidermis [9].
Immunofluorescence
Immunofluorescence was conducted in relapse lesions (n=3–5)
using antibodies and fluorochromes as outlined in Table S1, and
as described previously [9]. Images in each figure are presented
both as single color stains (green and red) located above the
merged image, so that one can appreciate the localization of two
markers on similar or different cells. Cells that co-express the two
markers in a similar location are yellow in color. A white line
denotes the dermo-epidermal junction. Dermal collagen fibers
gave green autofluorescence, and antibodies conjugated with a
fluorochrome often gave background epidermal fluorescence.
Microarray
RNA was extracted from full-thickness skin biopsies (NL, LS,
week 12 and relapse) of 4 relapsing patients that were the best
histological responders (first 4 patients in Table 1). Patients were
classified as responders based on normalization of epidermal
thickness, keratin 16 (K16) protein expression, restoration of a
granular layer, and orthokeratosis in week 12 biopsies [10]. RNA
was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA).
For each HGU 133 2.0 Affymetrix gene chip, 2 mg total RNA was
reverse transcribed, amplified, and labeled [11]. Experiments were
conducted in compliance with Minimum Information About a
Microarray Experiment guidelines. Tissue microarray data have
been deposited in NCBI’s Gene Expression Omnibus and are
accessible at GEO Series accession number GSE30768.
The analysis was conducted using R software (http://www.R-
project.org) with bioconductor packages (http://www.bioconductor.
org). CEL files were scrutinized for spatial artifacts by using the
Harshlightpackage[12].Classicmicroarrayqualitycontrolreportwas
obtained by using the affyQCReport package. Expression values were
obtained by using GCRMA algorithm. Probe-sets with standard
deviation (SD) greater than 0.1 and expression values greater than 3
inat least 2 samples were kept for further analysis (13405 probe-sets).
Expression values were modeled using mixed effect models with
Time as fixed effect and Patient as a random factor. Model
estimation and hypothesis testing were conducted in the framework
of limma. Comparisons of interest were assessed using moderated-t
test, and resulting p-values were adjusted for multiples hypothesis
using Benjamini-Hochberg approach. Probe-sets with fold change
(FCH) larger that 2 and false discovery rate (FDR) smaller than 0.05
were selected as efalizumab modulated genes.
RT-PCR was conducted for keratin 16 (K16) as previously
described [13].
Figure 1. Enrollment flowchart.
doi:10.1371/journal.pone.0030308.g001
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PBMCs were stained with CD11a-FITC (clone 25.3.1, binds to
an alternative epitope than the efalizumab-antibody binding site,
Immunotech) and CD14-APC (BD) in a standard manner.
Statistics
Mean PASI, absolute lymphocyte count, epidermal thick-
ness, and cell count data were analyzed using a Freidman test
(paired 1 way ANOVA). Median fluorescence intensity for
CD11a expression by flow cytometry was analyzed using a
paired Wilcoxon signed rank test. Significance was accepted as
p,0.05.
Results
Characteristics of patients who experienced a relapse
Eight patients experienced a relapse at weeks 14–22, and were
included in this study. Table 1 summarizes details of these patients.
Three patients were female, and five were male; the majority were
Caucasian (7/8), and the other patient was Hispanic. Figure 2A
and 2B demonstrate two patients with disease relapse, showing the
inflammatory nature of the relapse.
Mean PASI at baseline was 36.7, which was reduced to mean
21.7 by week 6 (p,0.05), and 10.4 at week 12 (p,0.001),
representing a mean decrease of 72% (Figure 3A). Four patients
met or exceeded PASI 75, and 7 exceeded PASI 50. At relapse, the
mean PASI was 33.5, which was significantly increased compared
to week 12 (p,0.01). All patients experiencing a recurrence of
disease after ceasing treatment met the criteria for relapse, which is
defined as a loss of 50% of PASI improvement over baseline. One
patient also met the criteria for rebound, defined as PASI 125% or
greater of baseline within 3 months of stopping therapy. Patients
who do not respond to therapy are actually more likely to
experience rebound [6], but in our cohort, the patient who
experienced rebound had a PASI 72 score. Those patients who had
disease relapse were treated with cyclosporine and/or restarted
efalizumab therapy.
Minimal residual effect of efalizumab at the time of
relapse
During treatment with efalizumab the absolute lymphocyte
count was measured by calculating total white blood cell count
times the percentage of lymphocytes, based on complete blood
count data [1]. At the end of treatment, there was an
approximately two-fold increase in the mean absolute lymphocyte
count compared to baseline (Figure 3B), indicative of an effect of
circulating efalizumab [1]. At the time of relapse there was a
significant reduction in circulating lymphocytes compared to week
12 of treatment (p,0.05), as efalizumab was cleared from the
circulation during this observation period and the lymphocytosis
was reversed. CD11a expression on monocytes (in the six patients
that could be measured) was reduced from baseline to week 12
from a mean of 105 to 66 (p=0.06) and was significantly re-
expressed at relapse to 121 (p=0.03). The normalization of the
lymphocyte count and the re-expression of CD11a at the time of
relapse indicate that efalizumab was no longer exerting an effect,
and thus the newly available CD11a now allows leukocytes to
move into the skin during relapse.
Histological responses
Epidermal thickness was measured during therapy and at the
time of relapse (Figure 3C). There was a significant increase in the
epidermal thickness in LS compared to NL skin (p,0.001),
improvement with treatment (p,0.05), and an increase at relapse
compared to week 12, although non-significant. K16 mRNA
expression was similarly increased in LS skin, decreased with
treatment at week 12, and increased again with relapse (all
p,0.01) (Figure 3D). Representative histological effects of
efalizumab (Figure 3E) and K16 staining (Figure 3F) demonstrate
normalization of psoriatic inflammation, and K16 expression by
week 12, and the histological features of relapse, which are
clinically consistent with psoriasis.
Leukocytic infiltration during treatment with efalizumab and at
the time of relapse was next evaluated (Figure 3G–I). Neutrophil
elastase was increased in relapse (Figure 3G), indicating the
presence of abundant neutrophils as the lesions returned, similar to
florid inflammatory or pustular psoriasis. CD3
+ T cells were
increased in relapse compared to the end of treatment (p,0.01,
representative staining in Figure 3H, cell counts in Figure 3I).
There was a negative correlation between lymphocytes in the
blood and cutaneous CD3
+ T cells (Spearman correlation co-
efficient r=20.5, p=0.0012) (Figure S2A). CD163
+ macrophages
were not increased in relapse compared to the end of treatment or
lesional skin (data not shown).
Table 1. Clinical data and PASI score on the study patients.
Gender
PASI
Wk 0
PASI
Wk 12
%W k1 2
to W0
a
PASI @
recurrence
%l o s so f
improvement Relapse
b
% change at
recurrence Rebound
c
F
d 60 2.7 296% 46.2 76% Y 77% N
M
d 12.2 3.4 272% 16.6 150% Y 136% Y
F
d 30.8 9.2 270% 35.8 123% Y 116% N
F
d 35.2 8.9 275% 42.9 129% Y 122% N
M2 4 3 . 8 284% 16.5 63% Y 69% N
M 35.2 11.4 268% 36.8 107% Y 105% N
M 49.8 8.9 282% 31.8 56% Y 64% N
M 46.2 34.8 225% 41.2 56% Y 89% N
a% change week 12 compared to week 0
ball patients experienced a relapse between weeks 14–22, defined as loss of 50% of PASI improvement from baseline [5,6].
conly 1 patient experienced a rebound, said to occur if the PASI is 125% or greater than baseline, or if new generalized pustular, erythrodermic or more inflammatory
psoriasis occurs within 3 months of stopping therapy [5,6].
dGenomic characterization on first 4 patients in this table.
doi:10.1371/journal.pone.0030308.t001
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psoriasis lesions
CD11c is the most useful and general marker of cutaneous
myeloid DCs [14], and representative staining for these cells is
shown in Figure 4A with cell counts in Figure 4B. At the time of
relapse, CD11c
+ myeloid DCs were increased in lesions compared
to the end of treatment (p,0.05), and alsoabove NL levels (p,0.01)
(Figure 4B). Other useful markers for myeloid DCs are blood
dendritic cell antigen (BDCA)-1/CD1c, which identifies a popula-
tion of resident DCs, and the mature DC marker CD83. Consistent
with previous anti-psoriasis treatments [10,15], BDCA-1/CD1c did
not change with disease state, efalizumab treatment or relapse
(Figure 4C). However, CD83
+ cells were increased in LS skin,
decreased with treatment, and increased with relapse (Figure 4D).
We have defined ‘‘inflammatory’’ myeloid DCs as CD11c
+
CD1c
2 cells [16,17]. Two-color immunofluorescence identified
many CD11c
+ cells (red) that were not CD1c
+ (green) (Figure 4E).
Cells expressing both colors are seen as yellow, which are the
resident population of dermal myeloid DCs. The frequency of
these inflammatory myeloid DCs can be calculated by subtracting
CD1c cell counts from CD11c [15], and there was an increase in
CD11c
+CD1c
2 cells at relapse (p,0.06) (Figure 4F).
We have recently identified that TRAIL/TNFSF10 is a marker
of these inflammatory myeloid DCs [18], and TRAIL co-localizes
with many CD11c
+ cells (Figure 4G). TNF and iNOS-producing
DCs (TIP-DCs) [16] are considered to be a subset of inflammatory
myeloid DCs in psoriasis [17], and there were abundant TNF and
iNOS producing cells (yellow cells) in lesional tissue at relapse
(Figure 4H). Thus, during a relapse, cells were present that have
been previously identified as integral cellular components of a
psoriasis lesion.
As murine studies have shown that a circulating monocyte
population may be precursors for TIP-DCs [19], two-color
immunofluorescence was also performed for CD11c versus
CD14 and CD16. CD14
+ cells were increased in relapsed lesions
(p,0.05, Figure S2B). We have previously shown that both these
markers are present on some CD11c
+ cells [9], and this was
confirmed in relapsed lesions (Figure 4I, J).
Genomic characterization of relapse
In order to further characterize the skin during relapse, samples
from four patients who responded to treatment and experienced a
relapse were hybridized to Affymetrix HGU 133 2.0 expression
chips (first four patients in Table 1). We explored the difference
between any of the time points (NL, LS, week 12 and relapse), at
FCH$2 and FDR,0.05, presented in Table S2. Unsupervised
clustering of the expression data for these DEGs (compared to
relapse) showed the first level of clustering of the NL and week 12
biopsies together, and second cluster with the LS and relapse
biopsies (Figure S1). There were no differentially expressed genes
between LS and relapsed skin (Figure 5A). The treatment effect
(Week 12 versus LS) and the Relapse effect (Relapse versus
Week12) were quantified and showed an excellent correlation
(Figure 5B). In terms of magnitude, change induced by treatment
Figure 2. Clinical photographs of two representative patients with disease relapse upon cessation of efalizumab treatment. (A)
Baseline lesions (left), response to efalizumab (center) and a marked erythematous psoriatic reaction 5 weeks after ceasing treatment (right). (B)
Baseline photographs showing upper leg psoriatic plaques (left) which responded to efalizumab at week 12 (center) and a relapse in the same
location (right). Note the inflammatory nature of the lesions during relapse.
doi:10.1371/journal.pone.0030308.g002
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16,
Adjusted R
2: 0.76), with a slightly larger effect in the relapse (64%
of the genes had larger effect in Relapse than Treatment). Almost
all genes that were improved by treatment were returned to LS
levels in the relapsed skin: 92% of the genes up-regulated by
efalizumab and 76% of the down-regulated genes were reversed
after relapse, but the relapse effect encompassed a larger number
of genes (Figure 5C). This indicates that the relapse at the genomic
levels is a return to psoriasis, but even ‘‘worse’’.
To better understand the transcriptome generated by these
studies, we used Gene Set Enrichment Analysis (GSEA) to identify
gene sets that were related to the psoriasis relapse phenotype
Figure 3. Clinical and histological response to efalizumab and during relapse. (A) Mean PASI scores, (B) circulating absolute lymphocyte
count, (C) epidermal thickness (mm), (all n=8) and (D) normalized keratin 16 (K16) mRNA expression (n=4), throughout the trial and at time of
relapse. Non-lesional (NL) and lesional skin (LS), error bars represent the standard error of the mean.
* p,0.05;
** p,0.01;
*** p,0.001. Representative
(E) haematoxylin and eosin (H&E), (F) K16 protein, (G) neutrophil elastase, (H) CD3
+ T cell immunohistochemistry, and (I) CD3
+ T cell counts, showing
the psoriasiform nature of the relapse lesion, with characteristic K16 staining, neutrophils and CD3
+ T cells. Bar is 100 mm.
doi:10.1371/journal.pone.0030308.g003
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30308Figure 4. Increased inflammatory myeloid DCs in relapsed lesions. (A) Representative immunohistochemistry and (B) counts of CD11c
+ cells
per mm in non-lesional skin (NL), lesional skin (LS), and in the index lesional plaque at weeks 2, 6 and 12 and time of disease relapse. (C) The numbers
of CD1c
+ cells did not change with treatment or relapse. (D) CD83
+ mature DCs followed the same pattern as CD11c
+ DCs. (E) There were many
inflammatory myeloid DCs in the relapsed lesions, shown by immunofluorescence as CD11c
+ cells (red) that were not co-expressing CD1c (and thus
were not yellow), and (F) quantified as CD11c
+ minus CD1c
+ cells. (G) Inflammatory CD11c
+ DCs were co-expressing TNFSF10/TRAIL. (H) TNF- and
iNOS-producing DCs (TIP-DCs) were found in relapsed lesions. CD11c
+ cells (red) co-expressing (I) CD14 and (J) CD16 (both green). Cells that co-
express the two markers in a similar location are yellow in color. A white line denotes the dermo-epidermal junction. Bar is 100 mm.
doi:10.1371/journal.pone.0030308.g004
Inflammatory Cells in Psoriasis Relapse
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30308(Relapse versus Week 12) (Table 2), as we have done previously for
the psoriasis phenotype (LS versus NL) [20]. The closer the
enrichment score (ES) to 1, the closer the ranking of the genes in
the gene set to those in the list being queried. When upregulated
(UP) and down-regulated (DOWN) gene sets are both enriched, a
connectivity score (CS) can be calculated, and again, the closer to
1, the higher the ranking.
GSEA analysis of the LS versus NL skin genes showed that the
patients in our study had typical or classic psoriasis at the time of
enrollment, as there was a high connectivity score (0.86) for genes
in this list compared to a published list of DEGs by our group [20].
In the relapse phenotype, there was a high connectivity score (CS)
for the psoriasis transcriptome (‘‘PSORIASIS_SF’’) [20] and many
of the gene sets that have been shown to be enriched in psoriasis
[20]. This included the gene sets of keratinocytes treated with IL-
22 (‘‘IL22 KC’’) and IFNc (IFNG KC’’) [21]; up-regulated genes
in keratinocytes treated with IL-17 plus TNF (‘‘IL17&TNF
KC_UP’’) [22], and IL-1 (IL1 KC_UP’’) [23]; and the terminal
differentiation gene set [24] was also enriched in relapse.
Furthermore, the gene set for inflammatory myeloid DCs [18]
was also enriched in the relapse transcriptome. Thus, relapse is
akin to a severe psoriasis clinical phenotype.
Discussion
Our study showed that in skin lesions that develop during
relapse when efalizumab is ceased, there were abundant T cells
and DCs. These are leukocytes commonly found in psoriasis
lesions [25]. The genomic transcriptome of relapse is also very
similar to lesional psoriasis skin [20]. These data suggest that the
lesions of relapse are typical psoriasis, in contrast to lesions that
develop while on therapy, which have reduced cutaneous T cells
[26]. Furthermore, this investigation supports current knowledge
of requisite cells for the development of a psoriasis lesion, namely
T cells and antigen-presenting cells, with all the products that they
make.
This study also supports our developing concept that there is a
resident myeloid DC population in normal skin, marked by
BDCA-1/CD1c, which does not change in number during
inflammation [10,15]. CD11c has been used as a marker of
interstitial myeloid DCs [27]. The numbers of CD11c
+ cells in
psoriasis are many fold greater than CD1c
+ cells, as CD11c
identifies both the resident myeloid DCs and a population of
‘‘inflammatory’’ myeloid DCs. In contrast to resident CD1c
+ DCs,
CD11c
+ cells are increased in psoriasis, reduced with treatment,
Figure 5. Genomic characterization of relapsed psoriasis lesions. (A) Venn diagram showing DEGs for different comparisons, week 12 versus
LS; week 12 versus relapse; relapse versus LS. There were no unique DEGs in relapse compared to LS skin. (B) Scatter plot showing an excellent
correlation between the ‘‘treatment effect’’ and ‘‘relapse effect’’. (C) Number of genes improved by treatment and reversed by relapse. Red blocks
were increased DEGs, green blocks were decreased DEGs.
doi:10.1371/journal.pone.0030308.g005
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inflammatory DCs are important pathogenic cells in psoriasis, as
they produce TNF, iNOS, IL-20, and IL-23, and are TRAIL
+
[10,11,16,17,18]. Nitric oxide produced by iNOS activity may
explain the marked erythema of these relapse lesions. These data,
and the observation that CD163
+ cells were not increased, suggest
a more critical role for inflammatory DCs than macrophages in
the relapsed psoriasis lesion.
CD11a is a component of the heterodimeric b2-integrin LFA-1,
which is essential in transmigration of leukocytes into tissues
during inflammation and homeostasis. The monoclonal antibody
efalizumab binds CD11a, blocks the function of the LFA-1
molecule binding to ICAMs, and prevents CD11a
+ leukocytes
from leaving the circulation, effectively trapping them there. This
explains the peripheral leukocytosis that occurs in all patients
taking adequate doses of efalizumab [1], which we also saw in our
patients. The most prominent mononuclear cells comprising the
leukocytosis are CD8
+ T cells, and there was also an increase in
circulating IFN-c
+ T cells during treatment [1]. IL-17-producing
T cells were not studied at that time as their role in autoimmune
diseases was just being appreciated. Thus, when the drug is
stopped suddenly, there is a reservoir of CD11a
+ CD8
+ T cells in
the circulation ready to pour into the skin leading to rapid onset of
severe psoriasis.
Our biopsies were taken when relapsed patients presented with
florid lesions,sothe abovemodeldoesnotfullyexplainthekineticsof
how new lesions of psoriasis develop. It is possible that CD8
+ IFN-c-
producing T cells enter the skin first, as they are ‘‘backed-up’’ in the
circulation, setting off a psoriatic inflammatory cascade via DC
activation, as proposed by Kryczek et al [28]. These CD8
+ Tc e l l s
induce chemokines for circulating DC-precursors, such as mono-
cytes, to enter the skin and become inflammatory myeloid DCs.
There is then an amplifying cycle of DCs and skin homing memory
T cells migrating into the skin to drive lesion development.
The concept of monocytes as precursor cells for inflammatory
DCs has been well studied in mice [29], with a relevant example
being Gr-1
hi CCR2
+ monocytes giving rise to TIP-DCs in the
spleens of mice infected with Listeria monocytogenes [19]. An increase
in CD14
+ cells, and co-localization of CD14 and CD16 with
CD11c
+ myeloid DCs in situ in our study, suggests that monocytes
may be precursor cells giving rise to the inflammatory DCs.
However, in contrast to lymphocytes, there was no direct
relationship between circulating monocytes, which remained
constant, and skin CD14
+ cells, whose pattern mirrored T cells.
At present, it is unclear both what circulating CD14
+ monocytes
become once they enter the tissues, and also exactly which myeloid
subset is the precursor of tissue inflammatory myeloid DCs. As the
monocytes quickly migrate into the skin, they may retain CD14
expression, which may explain why inflammatory DCs express
monocyte markers CD14 and CD16, but normal skin myeloid
DCs do not [9]. While there is a minor population of CD14
+ DCs
in normal skin that has been proposed to drive Th2 responses [30],
the identity and role of CD14
+ in psoriasis has not been specifically
studied, and CD14
+ cells may be a heterogeneous population of
either myeloid DCs or macrophages. Subsets of circulating CD14
+
cells may give rise to any or all of these populations of tissue-
resident myeloid cells.
The mechanism by which myeloid DC precursors enter the skin
is also not entirely known. CD14
+ monocytes were not increased in
the circulation while patients were on efalizumab [1], but there was
a trend of reduced expression of monocyte CD11a during
treatment, with significant increase in surface CD11a by the time
of relapse. Hence there is a pool of circulating monocytes with
available surface CD11a that can access the tissues at the time of
relapse. Secondly, there was increased genomic expression of many
myeloid cell chemokines at the time of relapse, namely CCL2,
CCL20, CXCL1, CXCL2, IL-8/CXCL8 (Table S1, Figure S2C).
CCL2 is a known monocyte chemokine, and indeed the
development of inflammatory DCs in mice is dependant on
CCR2, the CCL2 receptor [31]. There is abundant CCL20 protein
staining in psoriasis, which is chemotactic for CCR6
+ immature
DCs and Th17 cells [32,33]. Monocytes from patients on
efalizumab were shown to be deficient in their chemotaxis to IL-
8, but they responded to chemokines normally in the absence of
efalizumab [34]. These data suggest that monocyte chemokines
increase during the period after ceasing efalizumab, and perhaps
reach a threshold to set up a chemotactic gradient for inflammatory
myeloid DC precursors and memory Th17 cells to enter the skin.
Increased numbers of immune cells in relapse lesions suggests
that releasing the CD11a blockade upon cessation of efalizumab
treatment creates a rapid influx of these leukocytes into the skin,
resulting in the development of new psoriatic lesions in some
patients. It is as if efalizumab applies a brake to inflammatory
leukocytes, retaining them in the circulation, and when efalizumab
is ceased, the brake is released. As these cells enter the skin
abruptly over a few weeks, they may cause an inflammatory
psoriasis that is difficult to treat, usually requiring an additional
systemic agent. In our study, 40% of patients experienced severe
relapse. Our findings suggest that the major mechanism of action
of efalizumab is to ‘‘hold’’ pathogenic leukocytes in the circulation.
Relapsed psoriasis lesions that develop in the setting of efalizumab
withdrawal appear to be true psoriasis lesions, with all the
complement of leukocytes and gene expression found in stable
plaque psoriasis. At this stage, it is not clear which cell type is leading
the way, but both antigen-presenting cells, such as the CD11c
+
inflammatory myeloid DCs and T cells, are required. When
efalizumab treatment is withdrawn, the release of the CD11a
blockade causes a rapid influxof immune cells into the skin, resulting
in the development of new psoriatic lesions in some patients. In the
Table 2. GSEA analysis of published gene sets.
PATHWAY/GENE SET SIZE
a ES
b NES
c p-val FDR CS
d REF
e
LS vs NL:
PSORIASIS_SF_UP 551 0.88 3.89 0.000 0.000 0.86 [20]
PSORIASIS_SF_DOWN 680 20.83 24.29 0.000 0.000
Relapse vs Week 12:
PSORIASIS_SF_UP 569 0.85 4.26 0.000 0.000 0.84 [20]
PSORIASIS_SF_DOWN 694 20.82 24.25 0.000 0.000
IL22 KC_UP 11 0.86 2.16 0.000 0.000 0.84 [21]
IL22 KC_DOWN 10 20.82 22.05 0.000 0.000
IFNG KC_UP 907 0.42 2.19 0.000 0.000 0.34 [21]
IFNG KC_DOWN 332 20.25 21.23 0.050 0.128
IL17&TNF KC UP 31 0.87 2.82 0.000 0.000 [22]
IL1 KC_UP 48 0.75 2.68 0.000 0.000 [23]
TERMINAL DIFFERENTIATION 33 0.58 1.86 0.000 0.001 [24]
PS_INFLAMM DCS_UP 131 0.33 1.41 0.008 0.041 [18]
aSize, number of genes in gene set.
bES, enrichment score.
cNES, normalized enrichment score.
dCS, connectivity score.
eREF, reference for gene set.
doi:10.1371/journal.pone.0030308.t002
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